Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 2, 2005, Pages 179-188

  Jin, Jing ^a   Wang, Feng Peng ^b   Wei, Huailing ^c   Liu, Gengtao ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b SICHUAN UNIVERSITY   (China)

^c INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Bromotetrandrine; Modulator; Multidrug resistance

Indexed keywords

5 BROMOTETRANDRINE; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; MESSENGER RNA; PACLITAXEL; TETRANDRINE; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER; CELL LINE; CELL STRAIN KB; CELL STRAIN MCF 7; CYTOTOXICITY; DOSE RESPONSE; DRUG SENSITIVITY; FLUOROMETRY; FLUOROPHOTOMETRY; HUMAN; IC 50; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; MOUTH CARCINOMA; MULTIDRUG RESISTANCE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; XENOGRAFT;

EID: 12144264443     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0868-0     Document Type: Article

References (32)

1. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427
2. Thiebaut F, Tsururo R, Hamada H, Gottesmann MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug resistance gene product in normal human tissues. Proc Natl Acad Sci U S A 84:7735-7738
3. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38:1277-1287
4. List AA (1993) Multidrug resistance: clinical relevance in acute leukemia. Oncology 7:23-32
5. Yuen AR, Sikic BI (1994) Multidrug resistance in lymphomas. J Clin Oncol 12:2453-2459
6. Arao S, Suwa H, Mandai M, Tashiro H, Miyazaki K, Okamura H, Nomura H, Hiai H, Fukumoto H (1994) Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. Cancer Res 54:1355-1359
7. Hokmayer TA, Hisenbek S, Von Hoff DD, Roninson IB (1992) Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 84:1486-1491
8. Chan HSL, Haddad G, Thorner PS, DeBoer G, Lin YP, Ondrusek N, Yeger H, Ling Y (1991) P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325:1608-1614
9. Sanfilippo O, Ronchi E, De Marco E, Di Fronzo G, Silvestrini R (1991) Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine. Br J Cancer 27:155-158
10. Baldini N, Scotlandi K. Barbanti-Brodano G (1995) Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333:1380-1385
11. Tsuruo T, Ikda H, Tsukayoshi S, Sajurai Y (1981) Overcoming of vincristine-resistant in P388 leukaemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967-1972
12. Georges E, Sharom FJ, Ling V (1990) Multidrug resistance and chemosensitization: therapeutic implications for cancer chemotherapy. Adv Pharmacol 21:185-220
13. Pennock CD, Dalton WA, Roeske WR. Appleton CP, Mosley K, Plezia P, Miller TP, Salmon SE (1991) Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 83:105-110
14. Pirker R, FitzGerald DJ, Raschack M, Frank Z, Willingham MC, Pastan L (1989) Enhancement of the activity of immunotoxins by analogues of verapamil. Cancer Res 49:4791-4795
15. Sikic BI (1999) Modulation of multidrug resistance: a paradigm for translational clinical research in oncology and hematology. Oncology (Basel) 5:183-187
16. Fracasso PM, Brady MF, Moore DH, Walker JL, Rose PG, Letvak L, Grogan TM, McGuire WP (2001) Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol 19:2975-2982
17. Fisher GA, Lum BL, Hausdorff J, Sikic BI (1996) Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer 32A:1082-1088
18. Wang G, Lemos JR (1995) Tetrandrine: a new ligand to block voltage-dependent Ca2+ and Ca(+)-activated K+ channels. Life Sci 56:295-306
19. He QY, Meng FH, Zhang HQ (1996) Reduction of doxorubicin resistance by tetrandrine and dauricine in harringtonine-resistant human leukemia (HL60) cells. Zhongguo Yao Li Xue Bao 17:179-181
20. Tian H, Pan QC (1997) A comparative study on effect of two bisbenzylisoquinolines, tetrandrine and berbamine, on reversal of multidrug resistance. Yao Xue Xue Bao 32:245-250
21. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
22. 7402 cell line. Cancer Lett 135:97-105
23. Geran RI, Greenberg NH, MacDonald MM, Schumacher AM, Abbott BJ (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 3:1-12
24. Tsuruo T, Iida H, Kitatani Y, Yokota K, Tsukagoshi S, Sakurai Y (1984) Effect of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and Adriamycin in drug-resistant tumor cells. Cancer Res 44:4303-4307
25. Shinoda H, Inaba M, Tsuruo T (1989) In vivo circumvention of vincristine resistance in P388 leukemia with a novel compound, AHC-52. Cancer Res 49:1722-1726
26. Choi SU, Park SH, Kim KH, Choi EJ, Kim S, Park WK, Zhang YH, Kim HS, Jung NP, Lee CO (1998) The bisbenzyl-isoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein. Anticancer Drugs 9:255-256
27. Xu JY, Zhou Q, Shen P, Tang W (1999) Reversal effect of TTD on human multidrug resistant KBV200 cell line. J Exp Clin Cancer Res 18:549-552
28. Fu LW, Zhang YM, Liang YJ, Yang XP, Pan QC (2002) The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells. Eur J Cancer 38:418-426
29. Tunggal JK, Ballinger JR, Tannock IF (1999) Influence of cell concentration in limiting the therapeutic benefit of P-glycoprotein reversal agents. Int J Cancer 81:741-747
30. 30. Xiao SH, Wei GL, Lu R, Liu CX, Wang FP (2004) Studies on pharmacokinetics of bromotetrandrine in animals (II). Effect on interaction of bromoisotetrandrine and adriamycin on pharmacokinetics. Asian J Drug Metabol Pharmacol 4:61-64
31. Luker GD, Nilsson KR, Covey DF, Piwnica-Worms D (1999) Multidrug resistance (MDR1) P-glycoprotein enhances esterification of plasma membrane cholesterol. J Biol Chem 274:6979-6991
32. Rowinsky EK, Smith L, Wang YM, Chaturvedi P, Villalona M, Campbell E, Aylesworth C, Eckhardt SG, Hammond L, Kraynak M, Drengler R, Stephenson J Jr, Harding MW, Von Hoff DD (1998) Phase I and pharmacokinetic study of taxol in combination with biricodar, a novel agent that reverses multi-drug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol 16:2964-2976